 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...153154155156157158159160161162163...208209» |
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Efficacy and safety of anlotinib hydrochloride in the treatment of advanced bone and soft tissue sarcoma after failure of first-line chemotherapy. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5551;
P4
32.5% of patients had received for at least second-line prior therapy and 25% of patients had received apatinib as a previous treatment . Anlotinib is effective and safe in the treatment of bone and soft tissue sarcoma, and its efficacy is positively correlated with special types (such as ASPS, synovial sarcoma), effectiveness can also be observed in patients who have failed in other targeted therapy.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib plus ifosfamide and etoposide (IE) versus IE chemotherapy alone for relapsed or refractory osteosarcoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5549;
For osteosarcoma with multiple sites’ metastasis, apatinib plus IE demonstrated clinically meaningful antitumor activity in patients with recurrent or refractory osteosarcoma after failure of MAP/I chemotherapy or even single apatinib or IE treatment alone, with a positive effect on delaying disease progression . This combination deserves further investigation in prospective trials with manageable toxicity.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy of camrelizumab (SHR-1210) plus apatinib with or without stereotactic body radiotherapy (SBRT) as higher-line therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5325;
For patients treated with SBRT, the regimen may have better efficacy . Further investigation is warranted.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A real-world study of camrelizumab in the treatment of advanced lung cancer patients. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5270;
In this real-world study of lung cancer, most of the patients enrolled were patients with poor PS score and late stage, but the efficacy and safety of camrelizumab in patients with advanced lung cancer were still confirmed . The dominant population and combination therapy are still under study.
- AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A clinical study of camrelizumab combined with chemotherapy and sequential apatinib in the second-line treatment of patients with advanced non-small cell lung cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5265;
In this second-line clinical study of lung cancer, most of the patients enrolled were patients with poor PS scores and later stages, but the effectiveness and safety of carrelizumab in patients with advanced lung cancer were still confirmed . The dominant population and the combined treatment plan are still being studied.
- Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Safety and efficacy of chidamide in combination with decitabine plus anti-PD-1 camrelizumab after relapse or progression on decitabine-plus-camrelizumab in classical Hodgkin lymphoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5042;
P2
The preliminary result shows a high objective response rate with the combination of chidamide, decitabine and camrelizumab in patients with resistance to decitabine-plus-camrelizumab therapy . The addition of chidamide to decitabine-plus-camrelizumab has an acceptable safety profile, and does not trigger immune-related adverse events.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] G2M checkpoint signaling among six-cell proliferation-related pathway as a biomarker for prediction and prognosis in pancreatic cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4414;
Interestingly, different pathway correlated with AUC of different agents, such as gemcitabine (mitotic: r=0.706 [p = 0.01]), paclitaxel (MYC v2: r = -0.636 [p< 0.05]), apatinib (mitotic: r = -0.556 [p = 0.03]), palbociclib (E2F: r =0.675 [p< 0.01]), and sorafenib (G2M: r = -0.593 [p = 0.03]), for pancreatic cancer . Each proliferation-related pathway was predictive of the unique agent, and the G2M score predicts survival of pancreatic cancer.
- Opdivo (nivolumab) / Ono Pharma, BMS, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Anti-PD-1 antibody combined with albumin-bound paclitaxel and gemcitabine (AG) as first-line therapy and Anti-PD-1 monotherapy as maintenance in metastatic pancreatic ductal adenocarcinoma (PDAC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4373;
P=N/A
The ORR and DCR of chemotherapy-naive mPDAC patients receiving camrelizumab plus AG were high . Safety findings were consistent with previous data observed from camrelizumab or AG treatment; with no unexpected safety signals.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Application of radiotherapy before or during immunotherapy to enhance its efficacy in metastatic and recurrent liver cancer: A pilot study from the real-world data. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4350;
The application of radiation before or during PD-1 inhibitors delivery fostered the immune response and enhance the efficacy of immunotherapy with prolonged PFS and OS in recurrent and metastatic liver cancer . A phase II prospective trial is ongoing.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4304;
Therefore, imaging evaluation may be used to predict a pathological response and further guide clinical treatment decisions . Response rates (n=23).
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A phase 2 trial of apatinib combined with intensity modulated radiation therapy for patients with unresectable hepatocelluar carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4296;
Response rates (n=23). Apatinib in combination with IMRT was safe and effective in improving PFS and DCR, and suggested an encouraging anti-tumor activity in patients with unresectable advanced HCC.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Conversion hepatectomy for hepatocellular carcinoma with inadequate future- remnant- liver after portal vein ligation in combination with apatinib plus camrelizimab: A single-arm prospective pilot study (PLACES). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4292;
Apatinib in combination with IMRT was safe and effective in improving PFS and DCR, and suggested an encouraging anti-tumor activity in patients with unresectable advanced HCC. PVL in combination with apatinib plus camrelizimab followed by staged resection may be a safe and effective treatment option for HCC pts with insufficient FLR.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy and biomarker analysis of neoadjuvant carrizumab plus apatinib in patients with local advanced biliary tract cancers. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4286;
Elevated S100A8, IL1B, KIR2DL3 expression levels may indicate resistance in clinical response . Increased ECMES positive exhausted CD8 T cells and SIGLEC5 positive neutrophils were predictive of response in non-responder tumors.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4284;
TRAEs were acceptable, and long-term efficacy is reasonably expected . Summary of efficacy outcomes (n = 25).
- AiRuiKa (camrelizumab) / Incyte, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] A real-world study of camrelizumab in the treatment of hepatocellular carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4281;
Between Mar 12, 2020, and Dec 25, 2020, 63 patients were screened for eligibility, of whom 41 eligible patients received camrelizumab were recruited and among whom 15 received apatinib, 16 received lenvatinib, 2 received sorafenib and 1 received regorafenib . Camrelizumab showed promising efficacy and safety in pretreated Chinese patients with advanced hepatocellular carcinoma, and might represent a new treatment option for these patients.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Correlation of patient characteristics with clinical outcomes of camrelizumab combined with apatinib for unresectable hepatocellular carcinma (uHCC): An observational retrospective analysis. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4280;
The first up-to-date real-world evidence indicates that both the baseline and post-treatment AFP level might be independent prognostic factors to evaluate the therapeutic efficacy and clinical outcome on the combination therapy of camrelizumab and apatinib . While larger sample sizes and longer follow-up study are needed to verify reliability of statistical results.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: An open-label, single-center, single-arm clinical study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4277;
P2
Camrelizumab (200mg) were given intravenously every 3 weeks since the first day of RT until disease progression, or intolerable toxicity... In this study, RT combined with anti-PD-1 had an acceptable safety profile and indicated an effective treatment option in patients with unresectable HCC.
- AiRuiKa (camrelizumab) / Incyte, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Camrelizumab in combination with TACE for the treatment of unresectable hepatocellular carcinoma (HCC): A multicenter, single-arm, prospective real-world study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4274;
Q2W or Q3W) with or without antiangiogenic therapy (apatinib, lenvatinib, sorafenib, or regorafenib) at any stage of the TACE treatment . The treatment strategy of TACE in combination with camrelizumab with or without antiangiogenic therapy showed encouraging clinical efficacy and manageable toxicity profile in treating unresectable HCC, which provided a new treatment option for HCC.
- AiTan (rivoceranib) / HLB Bio Group, Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4256;
P2
We evaluated the CTCs counts and PD-L1 status on CTCs during treatment in a phase 2 clinical trial, where patients with previously treated gastric cancer received JS001 in combination with Apatinib . Our results reveal the potential of CTCs as a noninvasive CDx biomarker in patients with advanced GC/EGJC.
- Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Chemothery (pacitaxol or irinotecan), plus apatinib and sintilimab as second-/third-line treatment for advanced gastric cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4246;
Chemotherapy, plus apatinib and sintilimab demonstrated promising activity and manageable safety profile as second- even third-line treatment in advanced gastric or GEJ cancer . Demographics and baseline characteristics.
- AiRuiKa (camrelizumab) / Incyte, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4242;
Demographics and baseline characteristics. Neoadjuvant camrelizumab plus nab-paclitaxel and S1 is safe, feasible and effective, and the efficacy could be predicted by TIME, which is worthy of further investigation.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4238;
P2
43 patients (pts) with histologically confirmed stage II/III/IVa(cT2-4aN0-3M0) ESCC were enrolled from February 2020 to February 2021.The study was divided into two stages, stage 1: we administered 1 cycle of camrelizumab for induction therapy (200 mg q2 weeks); stage2: pts received 2 cycle of camrelizumab (200 mg every 3 weeks) plus docetaxel and nedaplatin, followed by surgery within 4̃6 weeks after neoadjuvant therapy completion . Camrelizumab in combination with preoperative chemotherapy followed by surgery for locally advanced ESCC showed promising downstaging effect and MPR with good tolerance, and its efficacy and safety could be further studied in later trials.
- [VIRTUAL] CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4213;
P2
Sintilimab, doublet chemotherapy, and apatinib might offer an opportunity of cure for stage IV gastric cancer . Trial ID: NCT04267549.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4210;
P4
In conclusion, more than 90% of the patients received a lower dose regimen, which indicate dosage of 500mg or lower is a tolerated exposure . Furthermore, dose at 500mg or lower produced similar efficacy to that more than 500mg.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4208;
P4
Furthermore, dose at 500mg or lower produced similar efficacy to that more than 500mg. This study confirms that apatinib has a well-established and manageable safety profile and survival benefit as third or later line therapy for patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma.
- Jie Bai Shu (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase Ⅱ, single-arm, exploratory research. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4207;
The pCR rate of 57.14% was higher than the expected 40% . This encouraging result promoted us to continue this phase Ⅱ study.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Efficacy and safety of PD-1 inhibitors as first- and second- line treatments for advanced gastroesophageal cancers: A network meta-analysis of phase III clinical trials. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4206;
the combination of PD-1 inhibitors with chemotherapy improves OS and PFS in previously untreated gastroesophageal cancers . Single-agent anti-PD-1 drugs improve safety in refractory disease, with no significant change in OS and PFS.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Association of genomic characterization with clinical benefits of anti-PD-1 antibody combined with FOLFOX as neoadjuvant therapy on locally advanced gastric or gastroesophageal junction adenocarcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4200;
P2
Aberrant activation of WNT pathway was reported to be associated with immune evasion . Our study demonstrated that CTNNB1/WNT-pathway-mut may be a promising predictor for clinical response of neoadjuvant immutherapy in GC/GEJC.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4198;
Our study demonstrated that CTNNB1/WNT-pathway-mut may be a promising predictor for clinical response of neoadjuvant immutherapy in GC/GEJC. This real-world population showed that camrelizumab as the first- or second-line therapy was an effective and safe treatment for patients with ESCC.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4197;
P2
This real-world population showed that camrelizumab as the first- or second-line therapy was an effective and safe treatment for patients with ESCC. Compared with placebo plus paclitaxel, the combination of apatinib with paclitaxel as second-line therapy significantly improved median PFS with an acceptable safety profile in patients with gastric cancer with peritoneal metastasis.
- AiRuiKa (camrelizumab) / Incyte, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4196;
The addition of camrelizumab to albumin paclitaxel and carboplatin was demonstrated encouraging clinical efficacy and acceptable safety as neoadjuvant therapy, and might be a favorable option for pts with locally advanced ESCC . Further registered clinical trials are expected.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4195;
Eligible patients diagnosed as resectable locally advanced GC/GEJC were randomized to receive neoadjuvant treatment, in arm A, the patients received FLOT alone (docetaxel 50 mg/m²; oxaliplatin 85 mg/m²; leucovorin 200 mg/m²; 5-FU 2600 mg/m², every 2 weeks), in arm B, the patients received FLOT combined with camrelizumab(camrelizumab 200mg intravenously every 3 weeks)... Camrelizumab combined with FLOT showed promising efficacy as neoadjuvant treatment for patients with locally advanced gastric or GEJ adenocarcinoma, with low complications and acceptable toxicity.
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
[VIRTUAL] A prospective, randomized, controlled, multicenter study of apatinib combined with S-1 plus docetaxel as adjuvant therapy for locally advanced gastric cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4194;
Combination of apatinib with S-1/docexal chemotherapy shows clinical benefits in locally advanced gastric cancer (T3-4aN+M0), with tolerable toxicity . The study is still ongoing to reach our final endpoint, DFS.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Efficacy and safety of intermittent versus continuous dosing schedule of apatinib combined with docetaxel as second-line treatment for advanced gastric cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4193;
P2
Apatinib administered intermittently (5 days on/ 2 days off) exhibited similar efficacy to continuous schedule, while with less toxicity . Intermittent dosing schedule of apatinib may be an option for second-line treatment of patients with advanced gastric cancer.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with SOX regimen in the first-line treatment of unresectable advanced or recurrent gastric cancer: A single-arm, prospective, open clinical study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4192;
The current number of enrolled cases is small, but the preliminary effect of immunotherapy combined with chemotherapy in first-line patients with advanced gastric cancer can still be seen . This trial will further explore the clinical efficacy and safety of immunotherapy in the first-line gastric cancer.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4189;
P2
EBV positive is not a good predictor for response to PD-1 inhibitors . Potential biomarkers are needed to identify EBVaGC patients who might respond to PD-1 inhibitors.
- paclitaxel / Generic mfg.
[VIRTUAL] Preoperative chemotherapy combined with PD-1 inhibitor in locally advanced operable or potentially resectable esophageal squamous cell carcinoma: A real world study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4185;
Since the study included some potentially resectable patients with late staging, the pCR rate may be lowered . The further study aims to find the efficient biomarker including PD-L1 expression and CD8+ T cell infiltration .
- dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine, Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4184;
P1
Pyrotinib combined with SHR6390 had shown acceptable safety profile and encouraging efficacy in refractory advanced HER2 positive solid tumors . Further study would be carried out at the dose in cohort A.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A real-world clinical study of camrelizumab in the treatment of esophageal cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4183;
In this real-world study of esophageal cancer, most of the patients enrolled were patients with poor PS score and late stage, but the efficacy and safety of Camrelizumab in patients with advanced esophageal cancer were still confirmed . The dominant population and combination therapy are still under study.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4119;
P2
Previous phase 2 trials have demonstrated the promising antitumor activity of dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab in HER2-positive metastatic CRC...The randomized phase 3 PHOEBE trial proved that the efficacy of pyrotinib was better than lapatinib when in combination with capecitabine in HER2-positive local relapsed or metastatic breast cancer... Pyrotinib combined with trastuzumab showed promising ORR with acceptable safety in patients with HER2-positive advanced CRC, suggesting a potential treatment option, especially in those without co-mutations.
- SHR7390 / Jiangsu Hengrui Medicine, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4118;
P1
SHR7390 plus camrelizumab showed a tolerable safety profile . Preliminary clinical activity was reported regardless of BRAF and MSI status, and future studies are warranted to further evaluate these results.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine
[VIRTUAL] Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4000;
Preliminary clinical activity was reported regardless of BRAF and MSI status, and future studies are warranted to further evaluate these results. Intratumoral and intertumoral heterogeneities in metastatic lesions on pretreatment 18F-FDG PET/CT could predict response to pyrotinib treatment in patients with HER2-positive breast cancer, which could provide information to guide treatment decisions.
- AiTan (rivoceranib) / HLB Bio Group, Balversa (erdafitinib) / J&J, Otsuka
[VIRTUAL] Genomic profiling by cell-free circulating tumor DNA in patients with recurrent adenoid cystic carcinoma (ACC) and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3992;
ctDNA can reveal additional therapeutic targets not present on tNGS and can be repeated serially . FGFR genomic abnormalities can be a driver mutation in patients with refractory advanced ACC and the activity of Erdafinib should be evaluated in this subset of patients with few therapeutic options.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Prediction of clinical efficacy by plasma concentration of apatinib in patients with solid tumor. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3976;
The plasma Ctrough of Apatinib can predict the clinical efficacy of patients with solid tumor . Perspective clinical studies with adequate sample size are required to validate our results.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Postoperative concurrent chemoradiotherapy plus apatinib in patients with malignant glioma: From one single research institute. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3909;
P=N/A
Compared with control group, apatinib group still improved mPFS by 2.57 months in patients with malignant glioma, but there was no statistical significance (P>0.05).The results also indicated that apatinib conferred a significant beneficial effect on PTBE improvement . All occurred adverse reactions were moderate and controllable.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real-world study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3705;
Pyrotinib demonstrated an encouraging efficacy and manageable safety in patients with advanced HER2+ breast cancer . More data would be analyzed and reported in the future.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Tumor mutation burden and PIK3CA mutations are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3677;
*Qiyun Shi and Juncheng Xuhong contributed equally . #Co-corresponding author (Dr .
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Tumor mutational burden, MSI-H, dMMR: Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2021
P2, N=32, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-κB Signaling Pathway. (Pubmed Central) - Apr 29, 2021
Apatinib inhibits the invasion and metastasis of human liver cancer cells by downregulating the expression of MMP-related genes. This may be achieved by inhibiting the activation of the NF-κB signaling pathway.
- | arketamine nasal spray (HR071603) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects (clinicaltrials.gov) - Apr 29, 2021
P1, N=40, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This may be achieved by inhibiting the activation of the NF-κB signaling pathway. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Jul 2020 --> Jul 2021